Home Featured Page 216

Featured

Latest

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and...

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

Psychedelic Research Bulletin: September 2021

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

1...215216217...304 Page 216 of 304

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and...

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

Psychedelic Research Bulletin: September 2021

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

EDITOR PICKS

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY